MedTrace Logo

PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC

NCT03829007 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2022-01-10

No results posted yet for this study

Summary

Non-invasive imaging of tumor PD-L1 expression with 89Zr-labeled durvalumab PET/CT predicts response to durvalumab.

Conditions

Interventions

DIAGNOSTIC_TEST

PD-L1 imaging

89Zr-durvalumab injection followed by a PET/CT scan 5 days after injection

DRUG

Durvalumab

Durvalumab treatment is initiated after the PET/CT scan in a fixed dose of 1500 mg iv q4w

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • carla van Herpen, Prof · Radboud University Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-15
Primary Completion
2020-12-17
Completion
2021-12-09

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03829007 on ClinicalTrials.gov